Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.

NCT Number	NCT04837339
Lead Sponsor	Hopital Foch
Conditions	Lung Transplant Rejection, Lung Transplant Failure, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Enrollment	900 participants
Start Date	2022-03-17
Primary Completion	2037-03 (estimated)
Study Completion	2037-03 (estimated)
Updated on ClinicalTrials.gov	2022-08-03